Truvian Health signed Siemens Healthineers on October 1 to help develop, manufacture and commercialize TruVerus, its benchtop blood analyzer. Financial terms were not disclosed. Siemens brings manufacturing capacity and global distribution, and the two companies say they will look at further diagnostics together.
TruVerus runs clinical chemistry, immunoassay and hematology off one sample and returns results in about 30 minutes, with the patient still in the building. The box holds a cell imager, an absorbance reader, a bead scanner, an automated pipettor and an onboard centrifuge, and it runs single-use reagent kits. FDA cleared the instrument and a kidney panel in December 2024, then cleared complete blood counts plus nine metabolic, cardiovascular and liver assays in January 2026.
Truvian was founded in San Diego in 2015 and raised a $105M Series C in 2021. Building the assay menu is the hard part of point-of-care chemistry, and putting instruments in retail pharmacies and physician offices is the expensive part. This deal buys the second one.